Abstract:ObjectiveTo investigate the real-world viral response of chronic hepatitis C (CHC) patients receiving direct-acting antiviral agent (DAA) treatment and its effect on liver stiffness measurement (LSM) and aspartate aminotransferase-to-platelet ratio index (APRI). MethodsThe CHC patients who were consecutively admitted to Tianjin Third Central Hospital from April 1, 2018 to November 30, 2018 and received DAA treatment were enrolled, and all patients were treated with DAA (without interferon) for 12-24 weeks. Virologic response was evaluated at week 12 after treatment ended, and the changes of LSM and APRI from baseline to week 12 after treatment were compared. The Wilcoxon rank-sum test was used for comparison of continuous data between two groups. ResultsA total of 212 CHC patients were enrolled in our study, among whom 35.4% had liver cirrhosis, and the patients with genotype 1b, 2a, 3a, or 6a accounted for 75.0%, 18.4%, 4.2%, and 2.4%, respectively. Of all patients, 174 completed the course of DAA treatment and the 12-week follow-up, and among these patients, 98.3% achieved sustained virologic response (SVR) at the end of DAA treatment and 95.4% acquired SVR at week 12 after the treatment ended. Among the patients with genotype 1b, 2a, 3a, or 6a, 96.3%, 93.1%, 80.0%, and 100%, respectively, achieved SVR at week 12 after the treatment ended. There were significant reductions in LSM ［9.8 (6.9-16.3) kPa vs 11.4(77-19.1) kPa, Z=-2.5, P=0.012］ and APRI ［0.34 (0.25-0.64) vs 0.76 (0.56-2.25), Z=-6.6, P＜0.001］ from baseline to week 12 after the treatment ended. The patients were divided into groups according to the presence or absence of liver cirrhosis at baseline, and the results showed that from baseline to week 12 after treatment ended, the non-liver cirrhosis group had a significant reduction in LSM ［7.6 (6.6-10.7) kPa vs 8.8 (7.2-13.0) kPa, Z=-2.7, P=0.007］, while the liver cirrhosis group had no significant change in LSM ［17.4 (12.7-22.1) kPa vs 19.8 (12.8-24.9) kPa, Z=-1.4, P=0.152］. There was a significant reduction in APRI from baseline to week 12 after treatment ended in the liver cirrhosis group ［0.73 (0.52-1.34) vs 1.37 (0.80-2.11), Z=-3.4, P＜0001］ and the non-liver cirrhosis group ［0.29 (0.21-0.36) vs 0.54 (0.31-0.95), Z=-6.8, P＜0.001］. ConclusionIn this real-world study, CHC patients treated with DAA achieve a high overall virological response rate, with significant improvements in LSM and APRI at week 12 after treatment ends.

Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals

Regression in Hepatic Fibrosis in Elderly Chinese Patients with Hepatitis C Receiving Direct-Acting Antiviral Treatment.

Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.

Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C Shows Liver Fibrosis Regression on Three Noninvasive Tests: A Puerto Rican Cohort

Title : Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study Running head : Liver stiffness for liver fibrosis monitoring Authors :

Evaluating Short-Term and Long-Term Liver Fibrosis Improvement in Hepatitis C Patients Post-Daa Treatment.

Virological Response to Direct-Acting Antiviral Therapy and Changes in Liver Fibrosis Indices in Chronic Hepatitis C Pa-Tients with Different Alanine Aminotransferase and Aspartate Aminotransferase Levels in a Real-World Setting

Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy

Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients after Direct-Acting Antiviral Therapy.

FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study

Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.

Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon Versus Direct-Acting Agents

Efficacy of direct-acting antiviral agents in treatment of chronic hepatitis C and its effect on liver stiffness and as-partate aminotransferase-to-platelet ratio index

Direct Antiviral Agent Treatment Leads to Rapid and Significant Fibrosis Regression after HCV Eradication.

Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients

A retrospective follow-up study of hepatitis C virus related cirrhosis treated with direct-acting antiviral agent

Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis

Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C

Pretreatment Predictors Associated with Improvement in Hepatitis C Virus Related Decompensated Cirrhosis after Direct-Acting Antiviral Therapy

Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years after SVR.